胸腔内注射尿激酶对结核性胸膜炎患者纤溶活性及胸膜肥厚的影响

发布时间：2018-06-14 12:14

  本文选题：结核性胸膜炎 + 尿激酶　； 参考：《广东医学》2014年10期

【摘要】：目的观察胸腔内注射尿激酶对结核性胸膜炎患者纤溶活性及胸膜肥厚的影响。方法 60例结核性胸膜炎患者分成尿激酶组和对照组,两组均予胸腔置管引流,并予3HRZE/9HR方案抗结核治疗,尿激酶组同时予胸腔内注射尿激酶。两组均于引流前后检测胸腔积液纤溶酶原激活剂抑制因子-1、组织型纤溶酶原激活物、Ⅲ型前胶原(PCⅢ),并于治疗结束时测定胸膜厚度。结果尿激酶组治疗后胸腔积液纤溶活性增高,PCⅢ下降。对照组治疗前后纤溶活性无明显变化,PCⅢ虽下降,仍高于尿激酶组。尿激酶组在胸膜厚度及粘连发生率均显著低于对照组。结论胸腔内注射尿激酶能增高胸腔积液纤溶活性及降低PCⅢ浓度,能减轻胸膜肥厚及减少胸膜粘连。
[Abstract]:Objective to observe the effect of intrathoracic injection of urokinase on fibrinolytic activity and pleural hypertrophy in patients with tuberculous pleurisy. Methods 60 patients with tuberculous pleurisy were divided into two groups: urokinase group and control group. Both groups were treated with thoracic tube drainage and 3HRZE / 9HR regimen. Urokinase group was treated with intrathoracic injection of urokinase. The plasminogen activator inhibitor -1 in pleural effusion, tissue plasminogen activator and type 鈪，

本文编号：2017340